NLR Calculator – Neutrophil-to-Lymphocyte Ratio

Calculate the Neutrophil-to-Lymphocyte Ratio (NLR), a simple and cost-effective biomarker of systemic inflammation derived from a routine complete blood count (CBC). Elevated NLR is associated with poor prognosis in cancer, cardiovascular disease, sepsis, and COVID-19.

NEUTROPHIL-TO-LYMPHOCYTE RATIO
--
137111725+
ANC
--
ALC
--
Inflammation Level
--
Clinical Significance
--

What is NLR?

The Neutrophil-to-Lymphocyte Ratio (NLR) is a simple biomarker of systemic inflammation calculated from a standard complete blood count (CBC). It represents the balance between innate immune response (neutrophils) and adaptive immune response (lymphocytes). An elevated NLR indicates a shift toward neutrophil-mediated inflammation, which can signal infection, stress, or malignancy.

First described as a prognostic marker in oncology, NLR has since been validated as a predictor of outcomes across a wide range of conditions including cardiovascular disease, autoimmune disorders, sepsis, and more recently, COVID-19 severity. Its simplicity, low cost, and wide availability make it an attractive marker for clinical decision-making.

NLR Formula

NLR = Absolute Neutrophil Count (ANC) ÷ Absolute Lymphocyte Count (ALC)

Both values are obtained from a standard CBC with differential. The absolute counts are preferred over percentages for accuracy. Normal ANC ranges from 1,500–8,000 cells/µL and normal ALC from 1,000–4,800 cells/µL.

Interpretation & Ranges

NLR ValueInflammation LevelClinical Interpretation
1–2NormalNo significant systemic inflammation
3–7Mild to ModerateLow-grade inflammation; monitor for underlying cause
7–11ModerateSignificant inflammation; evaluate for infection, tissue injury, or malignancy
11–17SevereSevere systemic inflammation; associated with poor prognosis in critical illness
>17CriticalExtreme inflammatory response; high mortality risk in sepsis and ICU patients

NLR in Immune Response

Immune Balance: Neutrophils vs Lymphocytes Neutrophils (Innate) First responders to infection Normal: 1,500–8,000 cells/µL Lymphocytes (Adaptive) Targeted immune response Normal: 1,000–4,800 cells/µL ÷ Normal Mild Moderate Severe Critical Higher NLR = More innate inflammation, less adaptive immunity

NLR in Cancer Prognosis

NLR has been extensively studied as a prognostic biomarker in oncology. Elevated pre-treatment NLR is consistently associated with poorer overall survival and disease-free survival across multiple cancer types:

  • Colorectal cancer: NLR > 5 associated with 35% reduction in overall survival
  • Non-small cell lung cancer: NLR > 5 predicts worse response to immunotherapy
  • Breast cancer: Elevated NLR correlates with larger tumor size and lymph node positivity
  • Hepatocellular carcinoma: NLR > 5 is an independent predictor of post-surgical recurrence
  • Pancreatic cancer: NLR > 5 associated with significantly reduced median survival

The proposed mechanism involves neutrophils promoting tumor growth through angiogenesis and immune suppression, while lymphopenia reflects a weakened anti-tumor immune response. NLR is increasingly used alongside traditional staging systems to guide treatment decisions.

NLR in COVID-19 & Sepsis

During the COVID-19 pandemic, NLR emerged as one of the most reliable early predictors of disease severity and mortality:

  • Mild COVID-19: NLR typically < 3.13
  • Severe COVID-19: NLR typically > 3.13 (sensitivity 87%, specificity 63%)
  • Critical COVID-19: NLR > 9.8 associated with ICU admission and mechanical ventilation

In sepsis, NLR values above 10 have been associated with significantly higher 28-day mortality rates. NLR can help identify patients who may benefit from early aggressive intervention and ICU-level care. Serial NLR measurements can track treatment response and guide escalation or de-escalation of therapy.

Normal White Blood Cell Values

Cell TypeNormal Range (cells/µL)% of Total WBC
Neutrophils1,500–8,00040–70%
Lymphocytes1,000–4,80020–40%
Monocytes200–8002–8%
Eosinophils100–5001–4%
Basophils20–100<1%
Total WBC4,500–11,000100%

Worked Example

A 55-year-old patient with newly diagnosed lung cancer has a CBC showing:

  • Absolute Neutrophil Count: 7,200 cells/µL
  • Absolute Lymphocyte Count: 1,400 cells/µL
NLR = 7,200 ÷ 1,400 = 5.14

An NLR of 5.14 falls in the mild-to-moderate inflammation range (3–7). In the context of lung cancer, an NLR > 5 is associated with poorer prognosis and may indicate a more aggressive tumor biology. This information can supplement traditional staging to guide treatment intensity discussions.

Frequently Asked Questions

What is a normal NLR?

A normal NLR is typically between 1 and 2 in healthy adults. Values between 2 and 3 may still be within normal limits depending on the clinical context, age, and individual baseline. NLR can be transiently elevated by exercise, stress, or minor infections.

Can NLR be used alone for diagnosis?

No. NLR is a non-specific marker of inflammation and should never be used in isolation for diagnosis. It is best used as an adjunct to clinical assessment, imaging, and other laboratory tests. Its strength lies in prognosis and risk stratification, not in identifying a specific disease.

How does NLR differ from CRP and ESR?

While CRP (C-reactive protein) and ESR (erythrocyte sedimentation rate) are also inflammatory markers, NLR has several advantages: it is obtained from a standard CBC without additional testing, it reflects the balance between two arms of the immune system, and it has demonstrated superior prognostic ability in some malignancies compared to CRP alone.

Does NLR change with age?

Yes, NLR tends to increase slightly with age. Studies have shown that healthy adults over 65 may have a baseline NLR of 1.5–3.0, compared to 1.0–2.0 in younger adults. Age-specific reference ranges should be considered when interpreting NLR values in elderly patients.